Synovial Macrophages Expression of OX40L Is Required for Follicular Helper T Cells Differentiation in the Joint Microenvironment

Cells. 2022 Oct 21;11(20):3326. doi: 10.3390/cells11203326.

Abstract

Signaling via the OX40/OX40L axis plays a key role in CD4+ T cell development, and OX40L expression is primarily restricted to antigen-presenting cells (APCs). This study was designed to assess the role of APC-mediated OX40L expression in the context of the development of rheumatoid arthritis (RA)-associated CD4+ T cell subsets. For these analyses, clinical samples were harvested from patients with osteoarthritis and RA, with additional analyses performed using OX40-/- mice and mice harboring monocyte/macrophage-specific deletions of OX40L. Together, these analyses revealed tissue-specific roles for OX40/OX40L signaling in RA. Specifically, higher levels of synovial macrophage OX40L expression were associated with the enhanced development of T follicular helper cells in the joint microenvironment, thereby contributing to the pathogenesis of RA. This Tfh differentiation was found to be OX40/OX40L-dependent in this synovial setting. Overall, these results indicate that the expression of OX40L by synovia macrophages is necessary to support Tfh differentiation in the joint tissues, thus offering new insight regarding the etiological basis for RA progression.

Keywords: OX40L; differentiation; follicular helper T cells; joint microenvironment; rheumatoid arthritis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arthritis, Rheumatoid*
  • Macrophages / metabolism
  • Mice
  • Receptors, OX40 / metabolism
  • T Follicular Helper Cells*
  • T-Lymphocyte Subsets / metabolism

Substances

  • Receptors, OX40

Grants and funding

This research was funded by the National Natural Science Foundation of China (grant number 82003761), the Joint Funds of Zhejiang Provincial Natural Science Foundation of China (grant number LYY22H310008), the Medical Science and Technology Plan Project of Zhejiang Province (grant number 2022485250). the Zhejiang Pharmaceutical Society Hospital Pharmacy Special Research Project (grant number 2021ZYY12), the Zhejiang Provincial Natural Science Foundation of China (grant number LQ22H040005), and the Public Welfare Technology Research Project of Zhejiang Province (grant number LGF21H160023). And the APC was funded by the National Natural Science Foundation of China (grant number 82003761).